Top 5 Income Companies To Watch For 2015

Top 5 Income Companies To Watch For 2015: Halozyme Therapeutics Inc.(HALO)

Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of recombinant human enzymes that transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefits. The company primarily offers recombinant human hyaluronidase, an enzyme that degrades hyaluronan, which is a matrix component in the skin, and facilitates the dispersion and absorption of drugs and fluids. Its portfolio of products and product candidates are developed based principally on intellectual property covering the family of human enzymes known as hyaluronidases. The company also provides Ultrafast Insulin program, a Phase II clinical trial product for the treatment of diabetes mellitus; and Enhanze technology, a proprietary drug delivery platform for subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as sma ll molecules and fluids. It offers PEGPH20, a new molecular entity that is in Phase I trial for the systemic treatment of tumors; and HTI-501, a recombinant human proteinase, which is in Phase 1/2 clinical trial used for the treatment of edematous fibrosclerotic panniculopathy (cellulite). The company has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; ViroPharma Incorporated; and Intrexon Corporation to apply Enhanze technology to the partners? biological therapeutic compounds. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Advisors' Opinion:

• [By Maxx Chatsko]

  The treatment will add to its quickly growing expertise in blood treatments and biologics. Speaking of which, Baxter and Halozyme (NASDAQ: HALO  ) had HyQvia approved for marketing in Europeearlier this year. The therapy boosts the immune systems of patients with pri! mary and secondary immunodeficiencies, and combines multiple therapies -- both intravenous and subcutaneous -- into one subcutaneous product. It also allows patients to administer treatment at home every three to four weeks. In other words, it knocks the convenience category out of the park. Halozyme has had a tumultuous life on the public market, so this could be just the stabilizer shareholders need.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/top-5-income-companies-to-watch-for-2015-3.html